Search results
Ted Danson Has Lived With Psoriasis for 50 Years—Here Are the Dermatologist-Approved Ways He Combats...
Eating Well via Yahoo News· 2 weeks agoActor Ted Danson and dermatologist Jennifer Soung shared the importance of seeking care for...
6 Psoriasis Home Remedies to Try
Healthline· 5 days agoThis means no home remedy can completely relieve your symptoms with a guarantee they won’t return someday. Psoriasis can be very unique to each...
These Pictures Will Help You Identify the Most Common Skin Rashes
Prevention via Yahoo News· 2 weeks agoFrom eczema to allergic reactions to bug bites, here’s what common skin rashes look like in photos,...
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Digital Journal· 12 hours agoEntered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027[1]Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials ...
Amgen (NASDAQ:AMGN) Shares Down 2.7% on Insider Selling
ETF DAILY NEWS· 1 day agoAmgen Inc. (NASDAQ:AMGN – Get Free Report) shares were down 2.7% on Monday after an insider sold shares in the company. The company traded as low as $301.09 and last traded at $302.91. Specifically ...
Amgen (AMGN) Scheduled to Post Earnings on Thursday
ETF DAILY NEWS· 1 week agoAmgen (NASDAQ:AMGN – Get Free Report) is set to announce its earnings results after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $3.82 per share ...
AbbVie (ABBV) to Release Quarterly Earnings on Friday
ETF DAILY NEWS· 2 weeks agoAbbVie (NYSE:ABBV – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, April 26th. Analysts expect the company to announce earnings of ...
Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $26.56
ETF DAILY NEWS· 5 days agoNeedham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Arcutis Biotherapeutics in a research note on Friday, April 12th ...
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 1 week agoA number of other analysts have also recently weighed in on the company. Truist Financial raised their price objective on AbbVie from $180.00 to $195.00 and gave the stock a buy rating in a ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 1 week agoAbbVie traded as low as $158.56 and last traded at $158.89. Truist Financial lifted their target price on shares of AbbVie from $180.00 to $195.00 and gave the stock a “buy” rating in a < ...
